financetom
Business
financetom
/
Business
/
CRH Q4 Adjusted Earnings, Revenue Rise; 2025 EPS Guidance Issued; Dividend Raised
News World Market Environment Technology Personal Finance Politics Retail Business Economy Cryptocurrency Forex Stocks Market Commodities
CRH Q4 Adjusted Earnings, Revenue Rise; 2025 EPS Guidance Issued; Dividend Raised
Feb 26, 2025 2:26 PM

04:57 PM EST, 02/26/2025 (MT Newswires) -- CRH (CRH) reported Q4 adjusted earnings late Wednesday of $1.45 per diluted share, up from $1.30 a year earlier.

Analysts polled by FactSet expected $1.44.

Revenue for the quarter ended Dec. 31 was $8.87 billion, up from $8.69 billion a year earlier.

Analysts surveyed by FactSet expected $9.00 billion.

The company said it expects full year 2025 EPS $5.34 to $5.80. Analysts are looking for $5.99.

CRH increased its quarterly dividend 6% to $0.37 per share, payable on April 16 to shareholders as of March 14.

Shares were down more than 2% in after-hours activity.

Comments
Welcome to financetom comments! Please keep conversations courteous and on-topic. To fosterproductive and respectful conversations, you may see comments from our Community Managers.
Sign up to post
Sort by
Show More Comments
Related Articles >
UN shipping agency delays decision on carbon price for one year amid splits
UN shipping agency delays decision on carbon price for one year amid splits
Oct 17, 2025
LONDON -A majority of countries at the U.N. shipping agency voted on Friday to postpone by a year a decision on a global carbon price on international shipping, after failing to reach consensus on the emissions reduction measure amid U.S. pressure. The decision to delay the deal is a blow to the European Union and other countries including Brazil which...
Bristol-Myers Squibb, SystImmune Report 'Promising' Results for Cancer Drug in Phase 1 Study
Bristol-Myers Squibb, SystImmune Report 'Promising' Results for Cancer Drug in Phase 1 Study
Oct 17, 2025
11:10 AM EDT, 10/17/2025 (MT Newswires) -- Bristol-Myers Squibb ( BMY ) and SystImmune said Friday that a phase 1 study of the antibody-drug conjugate iza-bren showed promising anti-tumor activity and manageable safety profile. Presenting data at the European Society for Medical Oncology Congress in Berlin, the companies said the trial showed a 55% confirmed response rate among patients receiving...
Canaccord Genuity Group Jumps Near 20%, Comments on Reports of Possible Sale of British Business
Canaccord Genuity Group Jumps Near 20%, Comments on Reports of Possible Sale of British Business
Oct 17, 2025
11:09 AM EDT, 10/17/2025 (MT Newswires) -- Canaccord Genuity Group ( CCORF ) , up near 20% to a multi-year high, Friday commented on a news article speculating about a potential sale of Canaccord's UK wealth management business. The company said in a statement that it routinely evaluates strategic initiatives which sometimes involve discussions with potential counterparties, however, there can...
Zealand Pharma major shareholder announcement: Van Herk Investments B.V.
Zealand Pharma major shareholder announcement: Van Herk Investments B.V.
Oct 17, 2025
Company announcement – No. 22 / 2025 Zealand Pharma ( ZLDPF ) major shareholder announcement: Van Herk Investments B.V. Copenhagen, Denmark, October 17, 2025 – Zealand Pharma A/S ( ZLDPF ) (“Zealand”) (CVR-no. 20045078), a biotechnology company focused on the discovery and development of innovative peptide-based medicines, today reports receipt on 16 October 2025 of notification pursuant to Section 38...
Copyright 2023-2026 - www.financetom.com All Rights Reserved